Biocon Biologics secures US market entry date for Bmab 1200, a Proposed Biosimilar to Stelara Ruchika Sharma1 March 2024 3:30 PM ISTStelara (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation of interleukin IL-12/23 associated immune diseases and has...
Biocon Biologics Biocon Campus (Site 1) facility gets 4 USFDA observations Ruchika Sharma1 March 2024 12:01 PM ISTBangalore: Biocon has recently announced that the U.S. Food and Drug Administration (USFDA) has issued Form 483s with 4 observations at...
Biocon Biologics, Sandoz Australia ink pact for biosimilars Trastuzumab, Bevacizumab Ruchika Sharma9 Feb 2024 12:30 PM ISTTrastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin - both biosimilars are available on the PBS and utilised for the...
Biocon Biologics, Sandoz ink pact for distribution of immune disorder injection Adalimumab in Japan Ruchika Sharma23 Dec 2023 12:30 PM ISTAdalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira (generic name: adalimumab (genetical recombination)) and is indicated for...
Biocon arm completes integration of Viatris biosimilars business in 120 countries Ruchika Sharma19 Dec 2023 11:43 AM ISTBengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful completion of the transition of the acquired...
Biocon arm concludes integration of Viatris biosimilar business in 31 European countries Ruchika Sharma30 Nov 2023 5:33 PM ISTBengaluru: Biocon Biologics Ltd, a subsidiary of Biocon Ltd has announced that the integration of the Viatris' biosimilars business in 31...
Biocon arm gets UK MHRA marketing authorisation for ophthalmic drug Yesafili Ruchika Sharma14 Nov 2023 11:29 AM ISTIt is highly similar to the reference product Eylea (aflibercept).
Biocon Biologics to divest dermatology, nephrology branded formulations business units in India to Eris Lifesciences for Rs 366 crore Ruchika Sharma9 Nov 2023 11:45 AM ISTThe divestiture is expected to close by the end of Nov 2023, subject to customary closing conditions.
Ex Cipla Global CFO Kedar Upadhye appointed as new CFO of Biocon Biologics Ruchika Sharma20 Oct 2023 2:30 PM ISTBengaluru: Biocon Biologics Ltd, a subsidiary of Biocon Ltd has announced that the Board of Directors of Biocon Biologics have appointed Kedar Upadhye...
Biocon Biologics arm gets OAI status from USFDA for Malaysia insulin facility Ruchika Sharma18 Oct 2023 12:30 PM ISTBengaluru: Biocon Sdn Bhd., a step-down subsidiary of Biocon Biologics Limited has received a communication from the U.S. Food and Drug...
Biocon Biologics gets European Commission nod for critical eye treatment medicine Yesafili Ruchika Sharma21 Sept 2023 1:30 PM ISTBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the European Commission (EC) has granted marketing authorization in...
Prove efficacy of Itolizumab for subcutaneous route: CDSCO panel Tells Biocon Biologics Dr. Divya Colin13 Sept 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Biocon...
